Genfit S.A. (GNFT)

USD 3.79

(4.12%)

Market Cap (In USD)

188.97 Million

Revenue (In USD)

28.56 Million

Net Income (In USD)

-28.89 Million

Avg. Volume

9574.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.31-6.423
PE
-
EPS
-
Beta Value
1.122
ISIN
US3722791098
CUSIP
372279109
CIK
1757064
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. M. Pascal Prigent
Employee Count
-
Website
https://www.genfit.com
Ipo Date
2019-03-27
Details
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.